



Morbidity Week 1-31 : January 1- August 5, 2017

Epidemiology Bureau  
Public Health Surveillance Division

## Trend in the Philippines

A total of **910** suspect leptospirosis cases were reported nationwide from January 1 to August 5, 2017. This is **71.1%** higher compared to the same time period last year (**532**).

## Geographic Distribution

Most of the cases were from the following regions: **NCR** (18.9%), **REGION XI** (12.3%), **REGION VI** (10.8%), **REGION III** (8.8%) and **REGION VIII** (7.9%).

Fig. 1 Suspect Leptospirosis Cases by Morbidity Week Philippines, as of August 5, 2017 (N=910)




Fig. 2 Suspect Leptospirosis Cases by Region Philippines, 2017 vs 2016





Fig. 3 Suspect Leptospirosis Cases by Region, Philippines, as of August 5, 2017 (N=910)



\*NOTE: Case counts reported here do NOT represent the final number and are subject to change after inclusion of delayed reports and review of cases.




## Leptospirosis Cases

Morbidity Week 1-31 : January 1- August 5, 2017

Epidemiology Bureau  
Public Health Surveillance Division

Fig. 4 Suspect Leptospirosis Cases by Morbidity Week,  
Philippines, as of August 5, 2017  
2017 vs 2016 (N=910)



### Profile of Cases

Ages of cases ranged from less than 1 to 76 years old (median = 30 years). Majority (86.9%) of cases were male. Most (14.1%) of the cases belonged to the age group of 20-24 years old (Fig. 5). There were 96 deaths (CFR = 10.55%). The 50-54 age group (Fig. 6) has the highest CFR (19.51%).

Fig. 5 Suspect Leptospirosis Cases by Agegroup and Sex  
Philippines, as of August 5, 2017 (N=910)





Fig. 6 Suspect Leptospirosis Case Fatality Rate (CFR) by  
Age Group, Philippines, as of August 5, 2017 (n=96)



\*NOTE: Case counts reported here do NOT represent the final number and are subject to change after inclusion of delayed reports and review of cases.





Morbidity Week 1-31 : January 1- August 5, 2017

Epidemiology Bureau  
 Public Health Surveillance Division

Table 1. Suspect Leptospirosis Cases & Deaths by Region  
 Philippines, 2017 vs 2016

Region	Cases			Deaths			
	2017	2016	% Change	2017	CFR (%)	2016	CFR (%)
I	70	48	45.8	13	18.57	7	14.58
II	53	26	103.8	2	3.77	1	3.85
III	80	82	-2.4	11	13.75	5	6.10
IV-A	31	32	-3.1	5	16.13	4	12.50
IV-B	3	11	-72.7	0	0.00	0	0.00
V	36	30	20.0	2	5.56	1	3.33
VI	98	72	36.1	9	9.18	9	12.50
VII	49	10	390.0	7	14.29	4	40.00
VIII	72	10	620.0	10	13.89	0	0.00
IX	8	12	-33.3	2	25.00	1	8.33
X	60	38	57.9	2	3.33	2	5.26
XI	112	17	558.8	6	5.36	4	23.53
XII	6	6	0.0	0	0.00	2	33.33
ARMM	3	0	0.0	0	0.00	0	0.00
CAR	23	13	76.9	2	8.70	0	0.00
CARAGA	34	10	240.0	3	8.82	0	0.00
NCR	172	115	49.6	22	12.79	10	8.70
<b>Total</b>	<b>910</b>	<b>532</b>	<b>71.1</b>	<b>96</b>	<b>10.55</b>	<b>50</b>	<b>9.40</b>

Figures 7-23. Leptospirosis Alert and Epidemic Thresholds per Region as of August 5, 2017

Fig. 7 Suspect Leptospirosis Cases by Morbidity Week  
 Region I, as of August 5, 2017 (n=70)





Fig. 8 Suspect Leptospirosis Cases by Morbidity Week  
 Region II, as of August 5, 2017 (n=53)



\*NOTE: Case counts reported here do NOT represent the final number and are subject to change after inclusion of delayed reports and review of cases.



## Leptospirosis Cases

Morbidity Week 1-31 : January 1- August 5, 2017

Epidemiology Bureau  
Public Health Surveillance Division

Fig. 9 Suspect Leptospirosis Cases by Morbidity Week  
Region III, as of August 5, 2017 (n=80)




Fig. 10 Suspect Leptospirosis Cases by Morbidity Week  
Region IV-A, as of August 5, 2017 (n=31)




Fig. 11 Suspect Leptospirosis Cases by Morbidity Week  
Region IV-B, as of August 5, 2017 (n=3)




Fig. 12 Suspect Leptospirosis Cases by Morbidity Week  
Region V, as of August 5, 2017 (n=36)




Fig. 13 Suspect Leptospirosis Cases by Morbidity Week  
Region VI, as of August 5, 2017 (n=98)





Fig. 14 Suspect Leptospirosis Cases by Morbidity Week  
Region VII, as of August 5, 2017 (n=49)



\*NOTE: Case counts reported here do NOT represent the final number and are subject to change after inclusion of delayed reports and review of cases.





## Leptospirosis Cases

Morbidity Week 1-31 : January 1- August 5, 2017

Epidemiology Bureau  
Public Health Surveillance Division

Fig. 15 Suspect Leptospirosis Cases by Morbidity Week  
Region VIII, as of August 5, 2017 (n=72)




Fig. 16 Suspect Leptospirosis Cases by Morbidity Week  
Region IX, as of August 5, 2017 (n=8)




Fig. 17 Suspect Leptospirosis Cases by Morbidity Week  
Region X, as of August 5, 2017 (n=60)




Fig. 18 Suspect Leptospirosis Cases by Morbidity Week  
Region XI, as of August 5, 2017 (n=112)




Fig. 19 Suspect Leptospirosis Cases by Morbidity Week  
Region XII, as of August 5, 2017 (n=6)





Fig. 20 Suspect Leptospirosis Cases by Morbidity Week  
ARMM, as of August 5, 2017 (n=3)



\*NOTE: Case counts reported here do NOT represent the final number and are subject to change after inclusion of delayed reports and review of cases.



## Leptospirosis Cases

Morbidity Week 1-31 : January 1- August 5, 2017

Epidemiology Bureau  
Public Health Surveillance Division

Fig. 21 Suspect Leptospirosis Cases by Morbidity Week  
CAR, as of August 5, 2017 (n=23)




Fig. 22 Suspect Leptospirosis Cases by Morbidity Week  
CARAGA, as of August 5, 2017 (n=34)





Fig. 23 Suspect Leptospirosis Cases by Morbidity Week  
NCR, as of August 5, 2017 (n=172)



### EDITORIAL BOARD

*Irma L. Asuncion*  
IRMA L. ASUNCION, MD, MHA, CESO IV  
Director IV, Epidemiology Bureau

*Genesis May J. Samonte*  
GENESIS MAY J. SAMONTE, MD, MSc, PHSAE  
OIC, Division Chief PHSD

*Mariel A. Dejesa*  
MARIEL A. DEJESA, MD, MPM  
Medical Officer IV

*Eune Cantata B. Corpuz*  
Eune Cantata B. Corpuz, RN  
Nurse III

*Jezza Jonah D. Crucena*  
Jezza Jonah D. Crucena, RN  
Nurse III